Dyslipidemia | Disease Landscape and Forecast | G7 | 2017


Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (CV) disease. With respect to lipid-modifying therapies, the greatest commercial success has come via agents reducing low-density lipoprotein (LDL) cholesterol, but research and development focusing on triglycerides, high-density lipoprotein (HDL) cholesterol, and other novel biomarkers is ongoing, all with the aim of ultimately providing CV benefits. During the 2016-2026 forecast period, the dyslipidemia market is expected to have two distinct phases: (1) early contraction due largely to the genericization of the dominant statin class, and ( 2) marked growth owing to the emergence of keenly awaited novel therapies, including Amgen’s Repatha, Sanofi/Regeneron Pharmaceuticals’ Praluent, The Medicine Company/Alnylam Pharmaceuticals’ inclisiran, Esperion Therapeutics’ bempedoic acid, AstraZeneca’s Epanova, Kowa Pharmaceuticals’ Parmodia, and Resverlogix’s apabetalone.Questions Answered: What impact will the genericization of AstraZeneca’s Crestor (rosuvastatin) and Merck’s Zetia/Ezetrol (ezetimibe) and Vytorin/Inegy (ezetimibe/simvastatin) have on the dyslipidemia market? How will CV outcomes data for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and omega-3 fatty acid compounds affect the market? How will the anticipated launches of novel oral products, including Esperion Therapeutics’ bempedoic acid, Resverlogix’s apabetalone, and Dalcor’s dalcetrapib, affect the use of the PCSK9 inhibitors? Which products will achieve the greatest use and why? What impact will the anticipated launch of Kowa’s pemafibrate and AstraZeneca’s Epanova have on the management of hypertriglyceridemia?Product Description:Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.Primary research: 24 country-specific interviews with thought leaders.Epidemiology: Primary and secondary prevention patients; high low-density lipoprotein cholesterol (LDL-C), low high-density lipoprotein cholesterol (HDL-C), high triglycerides (TGs), mixed dyslipidemia.Population segments in market forecast: Primary and secondary prevention patients.Emerging therapies: Phase II: 13 drugs; Phase III: 2 drugs; preregistration: 1 drug; registered: 3 drugs. Coverage of 14 select preclinical and Phase I products.

Questions Answered:

  • Several leading antidyslipidemic products, including AstraZeneca/Shionogi’s Crestor and Merck’s Zetia/Ezetrol will face generic competition early on in the 2014-2024 forecast period. How will the generic availability of these products affect medical practice in the major markets?
  • What will be the impact on drug sales?Many nonstatin therapies have been associated with poor trial results in recent years. What do thought leaders say about these therapies in light of these results? How will the treatment paradigm change?
  • The results of various CV outcomes trials (CVOTs) for several current and emerging therapies are expected across the forecast period. Now that there is much more emphasis on such data, how will these results impact medical practice?
  • How will the market share and sales of antidyslipidemic drugs with and without CVOT data be affected?
  • The highly efficacious proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors entered the market early in the forecast period. For what patient populations are these novels agents likely to be approved?
  • How will this keenly awaited class affect physician prescribing? What will be the impact on the potential for other novel treatments for hypercholesterolemia?
Login to access report